First human test of experimental drug BI 3034701 begins

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Part A: healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests. Part B: healthy male or female subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests. 2. Part A: age of 18 to 55 years (inclusive). Part B: age 18 to 65 years (inclusive). 3. Parts A and B: Signed and dated written informed consent in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial. 4. Further inclusion criteria apply Exclusion Criteria: 1. Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator. 2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 beats per minute (bpm). 3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance and, in particular: * Alanine aminotransferase (ALT) above upper limit of normal (ULN) + 20% * Aspartate aminotransferase (AST) above ULN + 20% * Gamma-Glutamyl-Transferase (GGT) above ULN + 20% * Lipase or amylase above ULN + 20% * Bilirubin above 1.2x ULN (except for cases of Gilbert's Syndrome) * Estimated glomerular filtration rate (eGFR) \< 80 mL/min/1.73 m² 4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator. 5. Further exclusion criteria apply.